The National Medical Products, on Sunday, said that China has authorized two domestically developed oral medicines for COVID-19 patients showing mild symptoms.
The drugs have been developed by Simcere Pharmaceutical Group and a unit of Shanghai Junshi Biosciences Co Ltd, the administration stated on its website. The drugs are meant for treating mild to moderate COVID-19 infections in adult patients.
Earlier in December, China abandoned its strict “zero COVID” policy on account of the protests against it, which allowed people to travel and the virus to grow across the country, raising demand for COVID treatment.
